Tag Archives: heart failure with preserved ejection fraction

Prevalence Among patients with a diagnosis of heart failure (HF), it is reported that up to 40-50% may have HFpEF.1 HFpEF also accounts for an increasing proportion of HF-related hospitalisations.2 There is a strong association between HFpEF, older age, and cardiovascular and non-cardiovascular comorbidities. As life expectancy and comorbidity rates rise, the proportion of HF patients with HFpEF and resulting impact of HFpEF on healthcare services is projected to increase. Clinical presentation Patients with HFpEF experience similar symptoms and signs to patients with HF with reduced ejection fraction (HFrEF), including breathlessness, fatig

Case presentation An 83-year-old man presented with progressive shortness of breath and moderate lower extremity oedema over a period of several months. His past medical history is notable for hypertension, non-insulin dependent diabetes, bilateral carpal tunnel syndrome and aortic stenosis. At the time of presentation he was found to have new-onset atrial flutter with rapid ventricular response. An echocardiogram demonstrated moderate concentric left ventricular hypertrophy and moderate aortic stenosis with an ejection fraction of 55% and mildly reduced right ventricular function. A left heart catheterisation confirmed the presence of modera

Landmark trials in heart failure – 30 years from CONSENSUS With 2017 marking the 30th year since the publication of CONSENSUS,1 which first reported a reduction in mortality with enalapril versus placebo in patients with advanced heart failure (HF), the BCS held a dedicated session to review the seminal clinical trials and advances in chronic heart failure management in this period. Dr Rosita Zakeri (Royal Brompton Hospital, London) reviewed this session for us and spoke to the BJC afterwards. Rosita Zakeri The era of vasodilator therapy for heart failure began in the 1990s. Professor Karl Swedberg (University of Gothenberg, Sweden) began